CClinicalTrials.gg
Active, not recruitingNCT06976307iADAPTUpdated Jul 8, 2026

Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial

An interventional study of High Carbohydrate Diet and Reduced Carbohydrate Diet in Disabilities, Obesity and Overweight and Prediabetes, sponsored by University of Alabama at Birmingham. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a sub-study to NCT04745572 to include a new cohort of participants with disabilities. This 16-week study will use an experimental approach called the Sequential Multiple Assignment Randomized Trial to help determine which combination and sequence of weight loss program features are most effective in people who are at risk for type 2 diabetes. Participants in the study will be initially randomized to consume either a high or reduced carbohydrate diet. After 4 weeks, participants will be identified as Responders (greater than or equal to 2.5% weight loss) or Non-Responders (less than 2.5% weight loss). Responders will continue with their initial randomized group for the remainder of the trial. Non-responders will be re-randomized to 2nd stage interventions of either including additional exercise counseling and training or beginning a time restricted eating protocol for the remainder of the trial.

02

Conditions studied

  • Disabilities
  • Obesity and Overweight
  • Prediabetes

Keywords

  • SMART
  • diet
  • exercise
  • weight loss
  • disabilities
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's planned enrollment of 30 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18-75 years of age
  • BMI of 27 kg/m2 or greater for ambulatory individuals and 22 kg/m2 for individuals with spinal cord injury. Adjustments will be calculated for those with amputations and/or limb indifference
  • at risk for developing type 2 diabetes (prediabetes)
  • One or more physical or mobility disabilities
  • Stable medication type and dosage for 3 or more months for medications likely to affect body weight and/or appetite
  • Willing to complete requirements for participation

Exclusion criteria

Exclusion Criteria:

  • Pregnant, planning to become pregnant or breastfeeding
  • Currently taking medication(s) for weight loss
  • Medical history of Type 1 or 2 Diabetes, using exogenous insulin, using prescription or OTC weight loss medications within the past 3 months, current alcohol or drug abuse or dependence, smoker with unstable habits in the past 3 months, pacemaker or other life-threatening medical implant, eating disorder(s)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High Carbohydrate Diet

    Enrollment in a group-based behavioral weight loss intervention based on the Diabetes Prevention Program curriculum with high carbohydrate diet plan.

    Behavioral: High Carbohydrate Diet

  • Experimental
    Reduced Carbohydrate Diet

    Enrollment in a group-based behavioral weight loss intervention based on the Diabetes Prevention Program curriculum with reduced carbohydrate diet plan.

    Behavioral: Reduced Carbohydrate Diet

Interventions

  • BehavioralHigh Carbohydrate Diet

    Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.

  • BehavioralReduced Carbohydrate Diet

    Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.

06

What researchers measure

Primary outcomes

  1. Change in glucose

    Serum glucose will be measured in a fasted state.

    Time frame: Baseline & Week 16

  2. Changes in body weight

    Measured on validated digital scale

    Time frame: Baseline, Week4, and Week 16

Secondary outcomes

  1. Changes in fat mass

    As measured by dual-energy X-ray absorptiometry (DEXA)

    Time frame: Baseline & Week 16

  2. Change in insulin

    Serum insulin will be measured in a fasted state.

    Time frame: Baseline & Week 16

  3. Changes in lipids

    Fasting serum concentrations of total cholesterol, HDL cholesterol, triglycerides, and LDL cholesterol

    Time frame: Baseline & Week 16

  4. Changes in QUICKI index

    Predictor of insulin resistance that will be calculated from glucose and insulin measures

    Time frame: Baseline & Week 16

  5. Changes in overall strength

    As measured by hand grip dynamometry

    Time frame: Baseline & Week 16

  6. Changes in aerobic fitness

    As measured by graded exercise test using arm crank

    Time frame: Baseline & Week 16

07

Study locations

1 site
  • Wellness Health and Research Facility (WHARF)
    Birmingham, Alabama 35209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06976307
Lead sponsor
University of Alabama at Birmingham
Responsible party
Christine Ferguson, PhD, RD, LD (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
May 16, 2025
Start date
Mar 24, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Jul 8, 2026

Study contacts

Christine Ferguson, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion